Roughly 90 patients have been treated with Bisantrene via the historic and the Israel trials for AML. At a guess several hundred doses administered for AML. Thousands of doses administered if you include patients treated historically with Bisantrene via trials for solid tumours.
So RACE have a big advantage relating to LILRB4, although this perhaps not known historically as potentially relevant in terms of mechanism of action for AML.
Sounds like FTO is upstream of LILRB4 and from all the data available has a broader application. So FTO is perhaps analogous to a master key.
Immuno-Onc seems to be targeting LILRB4 significantly.
Roughly 90 patients have been treated with Bisantrene via the...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.030(2.28%) |
Mkt cap ! $224.4M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.38 | $1.32 | $90.08K | 67.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5270 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.35 | 10000 | 1 |
View Market Depth
| Last trade - 12.19pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.35 |
Change
0.030 ( 5.08 %) |
||||
| Open | High | Low | Volume | ||
| $1.34 | $1.36 | $1.32 | 9962 | ||
| Last updated 12.42pm 10/05/2024 ? | |||||
| RAC (ASX) Chart |